Insulet (NASDAQ:PODD) Lowered to "Hold" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Insulet to “Hold” from “Strong Buy,” while the broader analyst consensus is also “Hold,” with 14 Buy, 11 Hold and 2 Sell ratings and an average price target of $195.40.
• Insulet reported strong quarterly results, posting $1.66 adjusted EPS versus the $1.47 consensus and revenue of $801.7 million, up 23.5% year over year.
• Despite the earnings beat, weaker retention among Type 2 diabetes users led to reduced 2026 revenue guidance, prompting several analysts to cut price targets and raising concerns about Omnipod adoption, recalls and potential legal exposure.

Insulet (NASDAQ:PODD - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "strong-buy" rating to a "hold" rating in a research note issued on Sunday.

Other analysts have also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft began coverage on shares of Insulet in a report on Tuesday, June 23rd. They issued a "buy" rating and a $190.00 target price on the stock. Benchmark lowered their price target on shares of Insulet from $250.00 to $185.00 and set a "buy" rating for the company in a report on Thursday. Evercore set a $180.00 price objective on shares of Insulet in a research report on Monday, July 6th. Royal Bank Of Canada reduced their price objective on shares of Insulet from $245.00 to $160.00 and set an "outperform" rating on the stock in a report on Thursday. Finally, William Blair began coverage on shares of Insulet in a research report on Wednesday, May 20th. They set an "outperform" rating for the company. Fourteen analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, Insulet currently has an average rating of "Hold" and an average price target of $195.40.

Insulet Trading Up 1.3%

PODD opened at $141.17 on Friday. The business has a fifty day moving average price of $155.42 and a 200 day moving average price of $193.60. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.81. Insulet has a 12 month low of $126.40 and a 12 month high of $354.88. The stock has a market capitalization of $9.79 billion, a price-to-earnings ratio of 26.39, a PEG ratio of 1.04 and a beta of 1.10.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.47 by $0.19. The company had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.Insulet's revenue for the quarter was up 23.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. Sell-side analysts expect that Insulet will post 6.51 earnings per share for the current fiscal year.

Insider Transactions at Insulet

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the company's stock in a transaction on Wednesday, June 3rd. The shares were bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the purchase, the director directly owned 9,041 shares of the company's stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.36% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Glenmede Investment Management LP raised its stake in Insulet by 1.6% during the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier's stock worth $708,000 after acquiring an additional 35 shares in the last quarter. Curi Capital LLC lifted its position in Insulet by 0.8% in the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier's stock valued at $1,365,000 after acquiring an additional 36 shares during the last quarter. Great Lakes Advisors LLC boosted its stake in Insulet by 1.5% in the fourth quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier's stock valued at $791,000 after acquiring an additional 40 shares in the last quarter. Camarda Financial Advisors LLC boosted its stake in Insulet by 0.5% in the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier's stock valued at $2,304,000 after acquiring an additional 40 shares in the last quarter. Finally, Larson Financial Group LLC grew its holdings in shares of Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 47 shares during the last quarter.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported strong second-quarter results, with revenue of $801.7 million, up 23.5% year over year, and adjusted EPS of $1.66 versus the $1.47 consensus estimate. The results indicate continued demand for the Omnipod platform despite emerging retention issues. Insulet Corporation Q2 2026 Earnings Call Summary
• Neutral Sentiment: Several law firms are seeking lead plaintiffs for a federal securities class action covering investors who purchased PODD shares between February 21, 2025, and May 26, 2026. The lead-plaintiff deadline is August 31, 2026; the allegations have not been proven. Pomerantz class-action announcement
• Negative Sentiment: Insulet reduced its 2026 revenue outlook after identifying weaker-than-expected retention among Type 2 diabetes users. Investors are concerned that the issue could temper Omnipod adoption and second-half growth, despite management maintaining that the broader growth opportunity remains intact. Insulet cuts 2026 revenue outlook
• Negative Sentiment: Analysts sharply cut their valuations following the guidance reduction. TD Cowen lowered its price target to $144 with a hold rating, UBS reduced its target to $150 with a neutral rating, JPMorgan cut its target to $152, and Leerink downgraded PODD to market perform. Benchmark and Stifel retained buy ratings but also lowered their targets. Analysts slash Insulet forecasts
• Negative Sentiment: Investor concerns also include two recent Omnipod recalls or voluntary medical-device corrections, which have raised questions about manufacturing quality, potential regulatory scrutiny and reputational damage. The newly filed lawsuit alleges securities-law violations related to these issues and the company’s disclosures. PODD shareholder alert

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source